Goldman Sachs Upgrades Myriad Genetics (MYGN) to Buy, 'differentiated financial profile at a discount'
Tweet Send to a Friend
(Updated - May 23, 2023 4:14 AM EDT)
Goldman Sachs analyst Matthew Sykes upgraded Myriad Genetics (NASDAQ: MYGN) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Goldman Sachs analyst Matthew Sykes upgraded Myriad Genetics (NASDAQ: MYGN) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
